CI Financial Corp.

DB:CF7 Stock Report

Market Cap: €3.0b

CI Financial Valuation

Is CF7 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CF7 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CF7 (€21.2) is trading above our estimate of fair value (€9.44)

Significantly Below Fair Value: CF7 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CF7?

Key metric: As CF7 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CF7. This is calculated by dividing CF7's market cap by their current revenue.
What is CF7's PS Ratio?
PS Ratio1.2x
SalesCA$3.59b
Market CapCA$4.43b

Price to Sales Ratio vs Peers

How does CF7's PS Ratio compare to its peers?

The above table shows the PS ratio for CF7 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.7x
MLP MLP
0.6x2.3%€641.6m
DWS DWS Group GmbH KGaA
1.9x-4.3%€7.7b
MUX Mutares SE KGaA
0.09x10.5%€484.6m
AR4 AURELIUS Equity Opportunities SE KGaA
0.1xn/a€394.9m
CF7 CI Financial
1.2x-3.2%€4.4b

Price-To-Sales vs Peers: CF7 is expensive based on its Price-To-Sales Ratio (1.2x) compared to the peer average (0.7x).

Price to Sales Ratio vs Industry

How does CF7's PS Ratio compare vs other companies in the DE Capital Markets Industry?

22 CompaniesPrice / SalesEstimated GrowthMarket Cap
MLP MLP
0.6x2.3%US$672.51m
MUX Mutares SE KGaA
0.09x10.5%US$508.01m
AR4 AURELIUS Equity Opportunities SE KGaA
0.2x0.01%US$500.05m
AR4 AURELIUS Equity Opportunities SE KGaA
0.1xn/aUS$413.77m
CF7 1.2xIndustry Avg. 2.8xNo. of Companies22PS048121620+
22 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CF7 is good value based on its Price-To-Sales Ratio (1.2x) compared to the German Capital Markets industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is CF7's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CF7 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio3.3x

Price-To-Sales vs Fair Ratio: CF7 is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CF7 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€21.20
€20.64
-2.7%
10.9%€21.71€15.61n/a6
Nov ’25€15.00
€15.04
+0.3%
14.2%€17.85€10.58n/a8
Oct ’25€12.00
€12.80
+6.7%
10.9%€14.63€10.64n/a8
Sep ’25€11.30
€12.80
+13.3%
10.9%€14.63€10.64n/a8
Aug ’25€11.00
€12.75
+15.9%
9.7%€14.01€10.67n/a9
Jul ’25€9.60
€12.88
+34.2%
10.2%€14.24€10.85n/a9
Jun ’25€9.40
€12.88
+37.1%
10.2%€14.24€10.85n/a9
May ’25€11.00
€13.50
+22.7%
10.2%€15.65€10.89n/a9
Apr ’25€11.60
€13.15
+13.4%
10.3%€15.69€10.92n/a9
Mar ’25€11.40
€13.15
+15.4%
10.3%€15.69€10.92n/a9
Feb ’25€11.20
€12.42
+10.9%
8.2%€14.43€10.99n/a7
Jan ’25€10.10
€11.83
+17.1%
11.0%€14.25€10.18n/a7
Dec ’24€9.35
€11.74
+25.6%
9.6%€13.58€10.19n/a7
Nov ’24€8.40
€11.83
+40.8%
9.6%€13.63€10.22€15.007
Oct ’24€10.80
€13.43
+24.4%
9.9%€15.32€11.14€12.007
Sep ’24€11.70
€13.08
+11.8%
9.3%€14.95€10.87€11.308
Aug ’24€11.30
€13.40
+18.6%
11.6%€16.44€10.96€11.009
Jul ’24€10.20
€12.80
+25.5%
15.9%€15.82€9.29€9.609
Jun ’24€8.90
€12.80
+43.8%
15.9%€15.82€9.29€9.409
May ’24€8.65
€12.62
+45.9%
9.8%€14.95€10.63€11.009
Apr ’24€8.30
€13.35
+60.8%
10.8%€16.32€11.11€11.609
Mar ’24€10.20
€13.35
+30.9%
10.8%€16.32€11.11€11.409
Feb ’24€10.80
€12.98
+20.2%
11.0%€15.76€10.96€11.209
Jan ’24€9.35
€13.18
+41.0%
11.8%€16.02€11.65€10.109
Dec ’23€10.00
€13.18
+31.8%
11.8%€16.02€11.65€9.359
Nov ’23€10.00
€13.58
+35.8%
12.3%€16.35€11.15€8.409

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Pepper Money

AU$581.0m

Operates as a non-bank lender in the mortgage and asset finance markets in Australia and New Zealand.

X95

AU$0.80

7D

-1.9%

1Y

13.6%

ORIX

JP¥3.8t

Provides diversified financial services in Japan, the United States, Asia, Europe, Australasia, and the Middle East.

OIX

JP¥20.40

7D

0%

1Y

22.9%

Yeahka

HK$4.2b

An investment holding company, provides payment and business services to merchants and consumers in the People’s Republic of China.

4YE

HK$1.18

7D

-6.3%

1Y

-27.2%